Beta Thalassemia Major in a Developing Country: Epidemiological, Clinical and Evolutionary Aspects

Mohamed Bejaoui and Naouel Guirat

Centre national de greffe de moelle osseuse, Tunis Tunisia

Correspondence to: Mohamed Bejaoui, centre national de greffe de moelle osseuse, 2 rue Jebel Lakhdar, 1007 Bab Saadoun Tunis Tunisia. Tel : +216 98317261, Fax : +216 71565368, E-mail:

Published: January 2, 2013
Received: June 4, 2012
Accepted: November 18, 2012
Meditter J Hematol Infect Dis 2013, 5(1): e2013002, DOI 10.4084/MJHID.2013.002
This article is available on PDF format at:
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited


Beta-thalassemia major (TM) remains to be one of the major health problems particularly in developing countries. Tunisia is a part of the Mediterranean countries mostly affected by this disease which is highly concentrated in small towns in families with low-income earners. The main objectives of this study are to provide a description of the demographic, clinical features and transfusion-related complications in patients with TM living in Tunisia. A standardized questionnaire was sent to clinicians throughout 33 different medical institutions caring for thalassemic patients. 391 transfusion dependant thalassemic patients with a median age of 10.7 years (range 3 months- 31 years) were included in the study.The majority  originated from the north west of the country. A moderate iron overload between 1501 and 2500ng/ml was found in 61patients, while 81 patients (26.9%) had a ferritin level more than 2500 ng/ml and greater than 5000ng/ml in 21 patients (6.9%). 51 patients died from complications related to their disease. Heart failure was the main cause of death. The incidence of cardiac, endocrine, and infectious complications will be reviewed. Preventive measures such as health education, carrier screening and premarital screening remain the best ways for lowering the incidence of these diseases, which might be reflected in financial saving, social s and health benefits.

TM is one of the most common hereditary diseases in Tunisia. Although its true incidence is unknown, it is estimated that 4.48 % of Tunisian population harbour thalassemic trait.[1] It remains a health problem in our country either for the clinicians who follow TM patients or to the patients themselves.
Lifelong red blood cells transfusion remains the main treatment for severe homozygous beta thalassemia even if hematopoietic stem cell transplantation is more and more utilized being the only definitive curative therapy for homozygous thalassemia.[2] In fact there are numerous risks and  considerable morbidity associated with chronic transfusion therapy.[3] Each unit of blood carries a small but definite risk of transmitting infections.[4] In addition, repeated blood exposure can induce alloimmunization to erythrocytes antigens, leading to difficulties in identifying compatible blood. Finally, long term erythrocyte transfusions inevitably lead to severe iron overload with its related complications involving the liver, the heart and the endocrine organs.[5] This study was aimed  at assessing the present epidemiological profile and the clinical features of TM major patients living in Tunisia.

Materials and Methods
The study was performed as a retrospective and descriptive observation. A standardized questionnaire was sent to clinicians throughout 33 different medical institutions in Tunisia caring for thalassemic patients. The questionnaire was used to collect demographic and clinical data (family history, age, sex, origin, consanguinity, age at diagnosis, age at the first blood transfusion and outcome); markers of iron overload (ferritin level, and/or serum iron); transfusion therapy and transfusions complications related to haemochromatosis (cardiac siderosis evaluated according to the results of the electrocardiogram and cardiac Doppler ultrasound, endocrinological complications), chelating therapy (date of onset, type of chelation, modalities).
Statistical analysis: Fisher‘s exact test was used to assess intergroup significance between categorical variables, and Student’s t-test was used to determine differences between continuous variables. The statistical analysis was carried out using software (SPSS version 11.5). A p value <0.05 was considered statistically significant.

Three hundred and ninety one transfusion dependant thalassemic patients [174 (44.5%) females and 217 males (55.4%); mean age 10.7 years; range 3 months to 31 years] were included in the study. Origin was determined in 382 cases. The majority of the patients come  from the west of the country; central west 117 cases (30%) and North West 107 cases (27.3%). It is important to note that the large migration flows from the western towns of Tunisia to the capital that contributed to the higher appearance of TM in Tunis. However, among the studied patients 22% were from small towns and cared in Tunis, only 5% of them live in the capital. Consanguinity was found in 244 among 324 studied patients (75.3%).
Most of the patients 325/391 (83.1%) were transfused at intervals of 3-4 weeks; 51 patients (13%) were transfused at an interval of 5-8 weeks and 15 patients (3.8%) poorly controlled and were transfused only  in an  emergency situation.). 126 patients (32.2%) received filtrated blood cells while only 14 patients (3.5%) received non phenotypically red blood cells. Transfusion-transmitted infections with hepatitis B and C viruses were diagnosed respectively in 2.3 % and 6.1% of patients. No infection with human immunodeficiency virus was found. A serum antibody screening was realized systematically before each transfusion for 209 patients (53.4%) and unevenly for 107 patients (27.3%). Alloantibodies were detected in 26 patients (8.2%) and belonged mainly to rhesus system (76.9%). Direct antiglobulin test was performed in 300 patients. Of the total 300 patients 105 (35%) developed auto antibodies.
Chelation therapy was administered to 341 patients (87.2%). Only the third of the patients received chelation therapy before they had completed their 3rd year and 33.3% of patients had started chelation at the age of 3 or later. Deferoxamine was the most commonly used iron chelator (224/391=57.3%) administered initially by intramuscular injection in 191 cases (85.2%) and 99 patients (51.8%) continued to use this route. Subcutaneous bolus injections were used for 61 patients and with infusion pumps for 64 other patients. At the time of the first survey deferasirox was administered to 16.7% and deferiprone was administered only to 12.4% of patients. Serum ferritin levels were evaluated in 301 patients. The majority of the patients revealed high ferritin levels.
Fifty-nine patients (19.6%) had serum ferritin levels between 1001 - 1500 ng/ml. A moderate iron overload between 1501 and 2500 ng/ml was found in 61 patients, while 81 patients (26.9%) had serum ferritin values above 2500 ng/ml and levels higher than 5000 ng/ml were determined in 21 patients (6.9%). The evaluation of serum ferritin levels revealed considerable differences depending onchelating therapy (Table 1).

Table 1.
Evaluation of mean ferritinemia in treatment groups.

During two years of the study, a gradual  decrease in mean ferritin levels was observed in patients treated with deferasirox versus deferoxamine either administered by pump or independently by injections (p = 0.001 and 0,02 respectively). Moreover, patients treated with Deferasirox presented with lower mean ferritin levels than those receiving deferiprone (p< 0.001). Analyses of the three treatment groups deferoxamine, deferasirox and deferiprone administered alone showed strong differences between serum ferritin concentrations and treatmentgroups (p=0.006). Cardiac disorders occurred in 63 among 318 studied patients (19.8%). Mean age of onset was 16.9 years (3-30). The youngest patient was died from heart failure related to severe anemia. Heart failure defined as dyspnea and/or peripheral edema with sinus tachycardia on electrocardiography without signs or symptoms of current or recent infection, thyroid disorders, autoimmune diseases or exposure to cardiotoxic agents was found in 34 among 63 studied patients (53.9%)
Pulmonary hypertension was found in 12.5% of the patients while arrhythmias were found only in five among the 63 studied patients. Mean serum ferritin level was significantly higher in patients with cardiopathy compared to those without cardiopathy (3000 versus 2053 ng/ml; p=0.005).
Delayed puberty was the most common endocrine complication in this study. It was observed in 46/90 (51.1%) of the patients. Among the 90 patients, 48 were males and 42 were females. Delayed puberty is more common in boys [26/48 boys (54.1%)] than in girls [20 /42 (47.6%)]. Growth retardation was seen in 64/239 (26.7%) of patients with mean age 12.9 years (3-22years). Thyroid function studies were available for 262 patients. Evidence of reduced organ activity was present in 18 cases (6.8%).Thirteen of 309 patients (4.2%) had diabetes mellitus, all diagnosed after the age of 9 years. The mean age at the time of diagnosis was 15.1 years. Mean serum ferritin level was found to be a contributing factor to endocrine disorders (Table 2).
Splenectomy was performed in 201/372 (54.0 %) of the patients [181 (90%) total splenectomy and 20 (9.9%) subtotal splenectomy]. Mean age of patients at splenectomy was 7 years. Routine vaccination against Streptococcus pneumonia, H. influenzae type b, and Neisseria meningitides had been received by 98.3%, 72 % and 85.2% of patients, respectively. Prophylactic antibiotics with benzylpenicillinbenzatine had been prescribed for 53.5 % of the patients however only 35.8% were treated with oral penicillin.
Cholelithiasis was observed in 7.9% of the patients (n = 31). Mean age at detection by ultrasonography was 13 years (range 3-22). Twenty four (77.4%) of the 31 patients with cholelithiasis had undergone cholecystectomy (6.1% of the whole population). Mortality occurred in 51/391 (13%) studied patients. The mean age of death was 10.48 years (2-21). Heart failure was the major leading cause of death: 20/51 (39%), followed by severe infections: 13/51 (25.4%). Five patients (9.8%) died of severe anemia. A significant difference was observed in the rate of mortality related to cardiopathy, type of chelation therapy and serum ferritin levels (Table  3).

Table 2.
Endocrine complications in patients with TM.

Table 3.
Mortality related complications.

33 deaths were reported during the deferoxamine treatment while only four deaths were reported during oral chelating therapy (p-value=0.001). All patients were followed up at UHC. Mean patient age at onset of the oral chelating treatment was 17 years (12-18years). Two patients were treated with deferasirox while two others had received deferiprone. Mean total period of oral chelating therapy period was two years. No correlation was observed between mortality and splenectomy.

Tunisia is a part of the Mediterranean countries mostly affected by thalassemia, one of the most common genetic diseases in the world. The prevalence of TM is especially high in countries where there are close family marriages.[6] Geographic distribution in this study demonstrated that TM is highly concentrated in small towns particularly in the western part of the country where there are  marriages between close relatives.
Blood transfusion and iron chelation remain the cornerstone of treatment for patients with TM.[7] However, there are several risks associated with chronic blood transfusions; firstly the risk of transmitting infections. In addition, long term erythrocyte transfusions inevitably lead to severe iron overload. Finally, repeated blood exposure can induce immunization, leading to difficulty in identifying compatible blood. Hepatitis C and B viruses are the  most common infection agents transmitted via transfusions and routine screening is performed for these agents throughout the world. In contrast to other studies,[8,9] the rate of transfusion transmitted infections with HCV is lower in our population. Alloantibodies were detected in 8.2% of our patients. These findings were in accordance with the results of Ahrens et al.[5] but were lower than those reported by Singer et al.[2] who reported a rate of alloimmunization of 44% among transfusion dependant thalassemia patients of predominantly Asian origin. This difference may be explained by several factors, family donation is frequently solicited in Tunisia explaining the antigenic homogeneity between donor’s antigens system and recipient’s RBC antigens. Another factor that could contribute to the low frequency found in the present study might be the early stage  of the  first blood transfusion for the majority of our patients. It has been thought that transfusion at an early age may offer some protection against red cell alloimmunization because of immune tolerance for young children.[3,10] In the present study the most frequently detected alloantibodies were anti rhesus system. This finding is in accordance with other reported data.[11,12] The prevalence of autoimmunization in multitransfused thalassemic patients in our population is high as compared to other countries. However, Bhatti et al.[13] found that 1.87% of their transfusion dependant thalassemic patients developed autoantibodies. Another study in Kuwait[10] reported that 11% of their patients developed autoantibodies. The higher rate found in our study may be explained by non phenotypically blood exposure in some of our patients.[14]
DFO was considered for a long time as the gold standard in iron chelation therapy. It has significantly improved  life expectancy and the quality of life of patients with iron overload.[15] But long-term management of iron overload is suboptimal in many patients, in part because of compliance issues associated with the parenteral administration regimen. Deferasirox, a once-daily oral iron chelator has proven safe and effective in reducing liver iron concentrations and serum ferritin levels in patients with various transfusion-dependant anaemia.[16,17] In our study and surprisingly, treatment with Deferoxamine led to a considerable reduction of mean plasma ferritin levels when administered by subcutaneous bolus injection. However, mean plasma ferritin levels were significantly higher compared to Deferasirox when administered by pump. This might be explained by a lack of chelating treatments in some hospitals  in  the country and poor compliance among some of the studied patients.
Heart disease may manifest as pulmonary hypertension, arrhythmias, systolic/diastolic dysfunction, pericardial effusion, myocarditis or pericarditis. 19.8% of our studied patients, suffered from heart disease, compared with a prevalence of 15.1% reported among 566 Sicilian thalassemic patients.[18] Comparison of the prevalence of cardiac involvement with other reports shows that heart failure is higher in Tunisia than in the other countries. In a cohort of 1146 patients born from 1960 through 1987, Borgna-Pignatti et al.[15] found that  the incidence of heart failure by 15 years of age account for 5% of the patients born between 1970 and 1974 and 2% in those born between 1980 and 1984. The reasons are not clear but are probably multiple and include less frequent transfusions, lower pre-transfusion hemoglobin level and inadequate chelation therapy.[19]
Iron-overload associated endocrinopathy is a frequently reported complication in chronically transfused TM patients with 60% of the patients with a dysfunction of at least one gland.[20,21] These include diabetes mellitus (DM), hypogonadism, hypothyroidism, hypoparathyroidism, and low bone mass. Hypogonadotropic hypogonadism remains a common endocrinopathy in multitransfused TM patients.[22] Our data are consistent with the Italian cohort in which hypogonadism was reported in nearly 50% of cases.[23] In contrast, the prevalence of growth retardation was higher (26.7%) than that reported from Italy, where it is found in less than 5% of the patients.[19,23] Hypothyroidism, diabetes mellitus and hypoparathyroidism are common particularly for patients in the second decade of life. Our overall diabetes rate of 4.2 % is lower than overall rate reported in Brittenham’s et al.[24] cohort of 59 patients, aged 7 to 31 years. It is comparable, however, to that reported from Italy, where it is found in less than 5% of the patients.[25] Mean serum ferritin level in TM patients with diabetes and those without diabetes was significantly different. However, no correlation was found between occurrence of diabetes and type chelation therapy.
Splenectomy is also beneficial in treating thalassemia major. It reduces patients’ transfusion requirement and iron overload and increases the main level of haemoglobin.[26] In our study 54.0% of patients underwent splenectomy. The high number of patients who were already splenectomized at the time of the first survey might indicate that previous transfusion therapy had been inadequate in at least some of them. The risk of invasive bacterial infection in splenectomized patients is well known. Data collected by Bisharat et al.[27] supports this concept. They reviewed 28 studies amounting to 6942 well-documented patients, 209 of whom developed invasive infection. Subtotal splenectomy may reduce the risk of postsplenectomy sepsis.[28] Nevertheless, there are not, at the moment, specific recommendations for this procedure which has technical drawbacks in this population including regrowth of the spleen and the need for reoperation.[29] Streptococcus pneumoniae was responsible for the majority of the infections (66%). It is followed for incidence by H. influenzae type b, Escherichia coli, and Neisseria meningitides. Thus  prevention and treatment of bacterial infections in splenectomized thalassemic patients are life-saving measures. Splenectomized patients must receive routine vaccination, including both live attenuated and killed vaccines, but they should also be immunized against Streptococcus pneumoniae, H. influenza type b, and Neisseria meningitides. However, vaccination does not completely protect against infection with encapsulated bacteria and prophylactic antibiotics have a role as well. According to other studies, cardiac failure and rhythm disturbances remain the main causes of death among our patients.[30,31] Severe anemia, if untreated, can result in high-output cardiac failure. Otherwise, cardiac failure may also result from multiple life-long transfusions. In addition infections are a frequent complication of thalassemias and they can be fatal. In our study, infections were the second cause of death after heart failure in polytransfused TM patients. Similar results were reported in Greece and in Italy.[15,32] The analysis of survival rates according to chelation treatment showed that patients treated with oral chelator have a survival rate of 92.2% compared to 66.66% in patients treated with DFO. Interestingly a standard care in UHC was associated with higher rate of survival. This may be explained by several reasons mainly, lack of knowledge, difficulties in follow-up due to low-income of concerned population and unavailability of chelator. To improve the situation, public education about thalassemia is of a great importance and should be carried out through periodic meetings addressed to health professionals including doctors and nurses working in the community, and family members. Also, all means of mass media are helpful as well as the sensitization through patient parents ‘associations that facilitates the contact with families and the diffusion of information through didactic supports (brochures, booklets ect…). In reality the whole problem still lies in the difficulties in the diagnosis of abnormal hemoglobin traits and in the very limited economic resources that do not permit to take in charge correctly the numerous patients already identified. this prevention programme in Sardinia,[33] the incidence of thalassaemia patients has decreased from 1:250 live births to 1:1000 live births. Similarly in Cyprus,[34] the incidence ofthalassaemia major cases dropped by 96%.

TM must be taken as a public health problem in Tunisia. Series of important conclusions can be drawn. First of all, a centralization of care institutions seems to be necessary. Intensified collaboration between smaller regional hospitals taking care of only a few patients and central medical institutions treating a greater number of patients is desirable. The use of individually adjusted intensification of chelation therapy in connection with suitable strategies for treating siderotic complications must be extended. Finally steps need to be taken to develop preventive measures like premarital screening, genetic counseling and prenatal diagnosis because of  the cost of treatment depending on the quality of care.

We gratefully acknowledge the contribution of Drs N.Gandoura (service de pédiatrie.Bizerte),  B.Meddeb (service d’hématologie hôpital Aiza othmana.Tunis), S.Barsaoui, A.Sammoud, Kh Boussetta, O.Ouali (hôpital d’enfants.Tunis), N.Tebib (Service de pédiatrie  hôpital la Rabta.Tunis), F.Bayoudh (Service de pédiatrie hôpital Militaire. Tunis), A.Bouaziz (Service de pédiatrie. Nabeul), L.Boughammoura, A.Khlif (Hôpital Farhat Hached.Sousse), A.Harbi (Hôpital Sahloul.Sousse), N.Gueddich (Service de pédiatrie.Monastir), T.Sfar (Service de pédiatrie.Mahdia), M.Hachjcha, M.Elloumi (Hôpital Hédi Chaker .Sfax), A.Gnaoui (Hôpital Régional de jendouba), A.Frej (Hôpital Régional du Kef), B.Chaabani (Hôpital Régional de Gafsa).


  1. Fattoum S. Evolution of Hemoglobinopathy Prevention in Africa: Results, Problems and Prospect. Mediterr J Hematol Infect Dis. 2009;1:e2009005. PMid:21415987 PMCid:3033160 
  2. Angelucci E, Pilo F, Targhetta C, Pettinau M, Depau C, Cogoni C, Usai S, Pani M, Dess L, Baronciani D. Hematopoietic stem cell transplantation in talassemia and related disorders. Mediterr J Hematol Infect Dis. 2009;1:e2009015. PMid:21415993 PMCid:3033161 
  3. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion dependant thalassemia patients of predominantly Asian descent. Blood 2000;96:3369-3373. PMid:11071629 
  4. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The retrovirus Epidemiology Donor study. NEngl J Med1996;334: 1685-1690. PMid:8637512  
  5. Ahrens N, Pruss A, Kohne A, Kiesewetter H, Salama A. Coexistence of autoantibodies and alloantibodies to red cells due to blood transfusion. Transfusion 2007; 47:813-816. PMid:17465945  
  6. Ghosh S., Bandyopadhyay SK, Bandyopadhyay R, Ro, Maisnam I, Ghosh M.K. A study on endocrine dysfunction in thalassaemia. J Indian Med Assoc2008; 106: 655- 659. PMid:19552099 
  7. Telfer P, Coen PG, Christou S, Hadjigavriel M, kolnakou A, Pangalou EK, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factorsover the period 1908-2004. Haematologica2006;91: 1187-1192. PMid:16956817 
  8. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J ClinPatho 1990;43: 638-640. 
  9. Angelucci E. Antibodies to hepatitis C virus in thalassaemia. Haematologica1994;79: 353-355. 
  10. Young PP, Uzieblo A, Trulock E, Lublin DM, Goodnough LT. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolyticanemia? Transfusion 2004; 44: 67-72. PMid:14692969  
  11. Ameen R, Al-Shemmari S, Al-Humood S, ChowdhurryRI,Al-Eyaadi O, Al-Bashir A. RBC alloimmunization and autoimmunization among transfusion-dependant Arab thalassemia patients. Transfusion 2003;43: 1604-1610. PMid:14617321  
  12. Gader AMA, Al Ghomlas AK, Al Momen AK. Transfusion medicine in developing country-Alloantibodies to red blood cells in multitransfused patients in Saudi Arabia. Transf. apheresis science 2008;39:199-204. 
  13. Bhatti FA, Salamat N, Nadeem A, Shabbir NJ. Red cell immunization in beta thalassaemiamajor. Coll Physicians Surg Pak 2004;14: 657-660. 
  14. Dhouib N, Mezri M, Hmida H, Mellouli F, Kaabi H, Ouderni M, et al. High frequency of autoimmunization among transfusion-dependent Tunisian thalassemia patients. Transf apheresis 2011;45: 199-20 
  15. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann N Y AcadSci1998;850: 227-231. PMid:9668544
  16. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011;22:115-120 
  17. Chimomas D, Smith AL, Braustein J, Finkelstein Y, Pereira L, Bergmann AK, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009;114:4009-4013. PMid:19724055 PMCid:2774541  
  18. Cao A., Galanello R., Rosatelli MC., Argiolu F., De Virgiliis S. Clinical experience of management of thalassemia: the Sardinian experience. Semin Hematol 1996; 33 :66-75 
  19. Rashid J, Khalil M, Natiq M, Anwar S, Nazir MM. Etiology of congestive heart failure in children. Pak Ped J 2003; 27: 145-51.
  20. Aydinok Y, Darcan S, Polat A, Kavakli K, Nigli G, Coker M et al. Endocrine complications in patients with beta-thalassemia major. Trop Pediatr 2002;48 :50-54. PMid:11866338 
  21. Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, et al.: Multi-Centre Study of Iron Overload Research Group. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135:574-582.
  22. Jensen CE, Tuck SM, Old J, et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur J Haematol 1997;59: 76-81. 
  23. Italian Working Group on Endocrine Complications in Nonendocrine Diseases Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol 1995;42:581-586. 
  24. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of desferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573. PMid:8047080  
  25. De Sanctis V, Eleftheriou A, Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004;2:249-255. PMid:16462705 
  26. Fosburg MT, Nathan D.G. Treatment of Cooley’s anemia. Blood 1990;76: 435-444. PMid:2198956   
  27. Bisharat N, Omari H, Lavi I. Risk of Infection and Death Among Post-splenectomy Patients. Journal of Infection 2001;43:182-186. PMid:11798256  
  28. Resende V, Petroianu A. Functions of the splenic remnant after subtotal splenectomy for treatment of severe splenic injuries. Am Surg2003;185:311- 315.  
  29. Rice HE, Oldham KT, Hillery CA, Skinner MA, O’Hara SM,Ware RE. Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg 2003;237:281-288. PMid:12560788  
  30. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta thalassemia syndromes: a decade of progress. Am J Med1 2005;18: 957-967. 
  31. Olivieri NF, McGee A, Liu P, Koren G, Freedman MH, Benson L. Cardiac disease-free survival in patients with thalassemia major treated with subcutaneous deferoxamine. An update of the Toronto cohort. Ann NY AcadSci 1990;612:585-586.  
  32. Ladis V, Chouliaras G, Bedousi H, et al. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y AcadSci 2005;1054 :445-450. PMid:16339695  
  33. Cao A, Rosatelli C, Galanello R, Monni G, Olla G, Cossu P. et al. The prevention of thalassemia in Sardinia. Clin Genet. 1989; 36:277-85. PMid:2598483 
  34. Buki MK, Qayum I, Siddiqui N. Prevalence and preventive measures for thalassemia in Hazara region of NWFP Pakistan. JAMC 1998; 10: 28-31. 

Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185